share_log

Altimmune | 8-K: Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Altimmune | 8-K: Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Altimmune | 8-K：Altimmune公布2024年第一季度财务业绩并提供业务最新情况
美股sec公告 ·  05/09 07:07
Moomoo AI 已提取核心信息
On May 9, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2024. The company announced ongoing enrollment in the IMPACT Phase 2b trial of pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top-line results expected in Q1 2025. Altimmune highlighted its cash position of $182.1 million and detailed its R&D expenses of $21.5 million, which included significant investment in the development of pemvidutide. General and administrative expenses rose to $5.3 million due to increased stock compensation and labor costs. The company also reported a net loss of $24.4 million, or $0.34 per share, for the quarter. Altimmune is preparing for an End-of-Phase 2 meeting with the FDA, anticipated in late Q3 2024, to discuss the Phase 3 pemvidutide obesity registrational program. The company's Chief Financial Officer, Richard Eisenstadt, signed off on the report.
On May 9, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2024. The company announced ongoing enrollment in the IMPACT Phase 2b trial of pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top-line results expected in Q1 2025. Altimmune highlighted its cash position of $182.1 million and detailed its R&D expenses of $21.5 million, which included significant investment in the development of pemvidutide. General and administrative expenses rose to $5.3 million due to increased stock compensation and labor costs. The company also reported a net loss of $24.4 million, or $0.34 per share, for the quarter. Altimmune is preparing for an End-of-Phase 2 meeting with the FDA, anticipated in late Q3 2024, to discuss the Phase 3 pemvidutide obesity registrational program. The company's Chief Financial Officer, Richard Eisenstadt, signed off on the report.
2024年5月9日，处于临床阶段的生物制药公司Altimmune, Inc. 公布了截至2024年3月31日的第一季度财务业绩。该公司宣布正在注册用于治疗代谢功能障碍相关性脂肪肝炎（MASH）的IMPACT 2b期试验，预计将在2025年第一季度公布最佳结果。Altimmune强调了其1.821亿美元的现金状况，并详细说明了其2150万美元的研发费用，其中包括对pemvidutide开发的巨额投资。由于股票薪酬和人工成本的增加，一般和管理费用增至530万美元。该公司还报告称，本季度净亏损2440万美元，合每股亏损0.34美元。Altimmune正在为预计于2024年第三季度末与美国食品药品管理局举行的第二阶段结束会议做准备，该会议将讨论第三阶段的pemvidutide肥胖注册计划。该公司的首席财务官理查德·艾森斯塔特签署了该报告。
2024年5月9日，处于临床阶段的生物制药公司Altimmune, Inc. 公布了截至2024年3月31日的第一季度财务业绩。该公司宣布正在注册用于治疗代谢功能障碍相关性脂肪肝炎（MASH）的IMPACT 2b期试验，预计将在2025年第一季度公布最佳结果。Altimmune强调了其1.821亿美元的现金状况，并详细说明了其2150万美元的研发费用，其中包括对pemvidutide开发的巨额投资。由于股票薪酬和人工成本的增加，一般和管理费用增至530万美元。该公司还报告称，本季度净亏损2440万美元，合每股亏损0.34美元。Altimmune正在为预计于2024年第三季度末与美国食品药品管理局举行的第二阶段结束会议做准备，该会议将讨论第三阶段的pemvidutide肥胖注册计划。该公司的首席财务官理查德·艾森斯塔特签署了该报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息